GlassScriptPhysician profile
Sharon Arnold
NPI 1306409271
$2,294.86
in general payments reported to CMS, 2019-2025
25 companies · $22.87 in 2025
The $22.87 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $748 · 2023: $576 · 2024: $440 · 2025: $22.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $381.45 | 2021-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $169.46 | 2021-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.20 | 2021-2023 | Jardiance |
| Sunovion Pharmaceuticals INC. | $145.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.00 | 2022-2024 | |
| Glaxosmithkline, LLC. | $122.28 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $120.93 | 2023-2024 | Gemtesa |
| Abbvie INC. | $120.15 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $106.91 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.70 | 2021-2023 | Xifaxan |
| Novo Nordisk INC | $93.02 | 2021-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $89.85 | 2021-2023 | Glassia |
| Amgen INC. | $89.33 | 2021-2023 | Repatha, Otezla |
| Lilly USA, LLC | $68.64 | 2021-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $67.89 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.66 | 2022-2024 | Rexulti |
| Grifols USA, LLC | $50.21 | 2021-2023 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $45.70 | 2022-2024 | Quviviq |
| Mylan Specialty L.P. | $34.68 | 2022 | |
| Axsome Therapeutics, INC. | $29.72 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $27.96 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $24.34 | 2021-2022 | |
| Insmed, INC. | $22.87 | 2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $16.98 | 2023 | |
| Exact Sciences Corporation | $13.73 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.